• ThromboGenics

    ThromboGenics announced that the Centers for Medicare and Medicare Services has published a permanent Healthcare Common Procedure Coding System code for Jetrea (ocriplasmin) in the United States. The code, J7316, will be effective January 2014.

    The code should streamline the reimbursement process for retina practices and instill higher confidence about reimbursement, ThromboGenics said.

    “We are confident that automation of the reimbursement process will be an important facilitator in this novel product’s uptake as U.S. physicians will now be reimbursed for Jetrea in a timelier and more efficient manner,” said ThromboGenics CEO Patrik De Haes, MD.

    Jetrea is the first pharmacological treatment option for symptomatic vitreomacular adhesion, including vitreomacular traction and macular holes up to 400 µm in diameter.

    Alcon holds the commercialization rights to Jetrea outside of the United States and is launching the drug in Canada, where it was approved in August.

    View this video on the ONE Network for more on ocriplasmin from the lead investigators.